ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 6.120-6.490 for the period, compared to the consensus estimate of 5.560. The company issued revenue guidance of $756.0 million-$776.0 million, compared to the consensus revenue estimate of $724.9 million.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock opened at $58.46 on Tuesday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm’s 50-day moving average is $57.23 and its two-hundred day moving average is $58.13. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $70.81. The company has a market capitalization of $1.23 billion, a PE ratio of -106.29 and a beta of 0.74.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ANIP shares. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday. Finally, StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

Insider Transactions at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. This represents a 4.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares in the company, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,300 shares of company stock worth $584,009 in the last three months. Company insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.